Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 6/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | HINT1 | P49773 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724396 | 0.91 | NT5E (0.40) | NT5E | |
| SCHEMBL19765997 | 0.88 | TMIGD3 (0.41) | CYP2C19HTR2CHTR2BTMIGD3HSP90B1 | |
| SCHEMBL20724397 | 0.87 | P2RY1 (0.43) | NT5E | |
| SCHEMBL20724581 | 0.86 | ADORA3 (0.50) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL20724479 | 0.86 | ADORA3 (0.50) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL20724314 | 0.85 | NT5E (0.35) | CYP2C19NT5ESLC29A1ADORA3ADORA1 | |
| SCHEMBL20724437 | 0.85 | NT5E (0.35) | CYP2C19NT5ESLC29A1ADORA3ADORA1 | |
| SCHEMBL19766095 | 0.82 | CYP2C19 (0.42) | CYP2C19HTR2CHTR2BTMIGD3HSP90B1 | |
| SCHEMBL19766096 | 0.82 | CYP2C19 (0.42) | CYP2C19HTR2CHTR2BTMIGD3HSP90B1 | |
| SCHEMBL19765821 | 0.81 | P2RY1 (0.39) | HTR2CHTR2BNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | Atea Pharmaceuticals, Inc. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | MTAP, NSUN2, PNP | CYP2C19 4552/4885HTR2C 2753/4885HTR2B 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.